Invivyd (NASDAQ:IVVD) Receives “Buy” Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Invivyd (NASDAQ:IVVD) in a research note published on Tuesday morning,Benzinga reports. HC Wainwright currently has a $10.00 price target on the stock.

IVVD has been the subject of a number of other reports. Morgan Stanley decreased their target price on Invivyd from $9.50 to $3.55 and set an “overweight” rating for the company in a research report on Wednesday, November 20th. EF Hutton Acquisition Co. I upgraded Invivyd to a “strong-buy” rating in a report on Wednesday, October 30th. Finally, D. Boral Capital reissued a “buy” rating and issued a $9.00 price target on shares of Invivyd in a research report on Monday. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $7.89.

Invivyd Stock Up 17.9 %

Shares of NASDAQ IVVD opened at $1.25 on Tuesday. Invivyd has a 12-month low of $0.35 and a 12-month high of $5.10. The firm has a market cap of $149.53 million, a PE ratio of -0.64 and a beta of 0.61. The company’s fifty day simple moving average is $0.51 and its 200 day simple moving average is $0.82.

Insider Activity

In related news, Director Terrance Mcguire sold 150,000 shares of the stock in a transaction on Monday, December 9th. The stock was sold at an average price of $0.61, for a total value of $91,500.00. Following the completion of the sale, the director now directly owns 4,538,079 shares of the company’s stock, valued at approximately $2,768,228.19. This represents a 3.20 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders have sold 816,466 shares of company stock worth $423,214 over the last 90 days. 17.90% of the stock is currently owned by corporate insiders.

Institutional Trading of Invivyd

Institutional investors have recently made changes to their positions in the company. Barclays PLC boosted its holdings in Invivyd by 179.6% during the third quarter. Barclays PLC now owns 117,973 shares of the company’s stock worth $120,000 after purchasing an additional 75,780 shares during the last quarter. State Street Corp boosted its stake in shares of Invivyd by 3.7% in the 3rd quarter. State Street Corp now owns 1,018,640 shares of the company’s stock worth $1,039,000 after buying an additional 35,904 shares during the last quarter. Proficio Capital Partners LLC bought a new position in shares of Invivyd in the third quarter valued at approximately $27,000. Cubist Systematic Strategies LLC increased its position in shares of Invivyd by 66.1% during the second quarter. Cubist Systematic Strategies LLC now owns 134,452 shares of the company’s stock valued at $148,000 after acquiring an additional 53,499 shares during the last quarter. Finally, Marshall Wace LLP lifted its holdings in Invivyd by 4.2% during the second quarter. Marshall Wace LLP now owns 786,899 shares of the company’s stock worth $866,000 after acquiring an additional 31,992 shares during the period. Institutional investors own 70.36% of the company’s stock.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.